山东新华医疗器械股份有限公司董事会 关于2024年度募集资金存放与使用情况的专项报告 根据《上海证券交易所股票上市规则》、《上市公司监管指引第2号 -- 上市 公司募集资金管理和使用的监管要求》和《上海证券交易所上市公司自律监管指 引第 1 号 -- 规范运作》等有关规定,现将山东新华医疗器械股份有限公司(以 下简称"公司"或"新华医疗")2024 年度募集资金存放与实际使用情况报告 如下: 资计划的正常进行,保护投资者的权益,根据《上市公司监管指引第2号 -- 上 市公司募集资金管理和使用的监管要求》、《上海证券交易所上市公司募集资金管 理办法》等相关规定,结合公司实际情况,对募集资金实行专户存储制度,对募 集资金的存放、使用、项目实施管理、投资项目的变更及使用情况的监督进行了 规定。 2023 年 3 月,公司和保荐机构中信建投证券股份有限公司(以下简称"中信 建投证券")分别与中国工商银行股份有限公司淄博高新支行、兴业银行股份有 限公司淄博分行、招商银行股份有限公司淄博分行、中国银行股份有限公司淄博 分行签署了《募集资金专户存储三方监管协议》前述协议与上海证券交易所《募 集资金专户存储三方监管协议(范本 ...

山东新华医疗器械股份有限公司董事会 关于独立董事独立性情况的专项意见 山东新华医疗器械股份有限公司(以下简称"公司")董事会共有四位独立 董事,分别为顾维军先生、潘爱玲女士、姜丽勇先生、黎元先生,四人在 2024 年度任职时间均为 2024年1月1日-2024年12月31日。 公司于近日收到四位独立董事提交的《独立董事关于 2024 年度独立性的自 查报告》,公司董事会对四位独立董事的独立性情况进行了评估,并出具如下意 见: 公司四位独立董事顾维军先生、潘爱玲女士、姜丽勇先生、黎元先生符合 《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《上海证券 交易所上市公司自律监管指引第1号一规范运作》中对独立董事独立性的相关 要求,在 2024年度不存在影响独立性的情形。 山东新华 ...

按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 □是 √否 公司代码：600587 公司简称：新华医疗 山东新华医疗器械股份有限公司 2024年度内部控制评价报告 山东新华医疗器械股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管 ...

关于山东新华医疗器械股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：山东新华医疗器械股份有限公司 审计单位：天职国际会计师事务所（特殊普通合伙） 联系电话：0531-82069926 控股股东及其他关联方资金占用情况的专项说明 天职业字[2025]12129 号 山东新华医疗器械股份有限公司董事会: 我们审计了山东新华医疗器械股份有限公司(以下简称"新华医疗")财务报表,包括2024 年12月31日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公司现金 流量表、合并及母公司股东权益变动表以及财务报表附注,并于2025年4月28日签署了天职业 字[2025]12133号标准无保留意见的审计报告。 根据中国证监会、公安部、国资委、中国银保监会《上市公司监管指引第8号 -- 上市公司 资金往来、对外担保的监管要求》和证券交易所相关文件要求,新华医疗编制了后附的2024年 度非经营性资金占用及其他关联资金往来情况汇总表(以下简称"汇总表")。 编制和对外披露汇总表,并确保其真实性、合法性及完整性是新华医疗管理层的责任。 ...

一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-021 山东新华医疗器械股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 3 日 9 点 00 分 召开地点：淄博市高新技术产业开发区泰美路 7 号新华医疗科技园办公楼三 楼会议室 股东大会召开日期：2025年6月3日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 3 日 至2025 年 6 月 3 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开 ...

山东新华医疗器械股份有限公司 第十一届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届监事会第十八次会议于 2025 年 4 月 18 日以通讯和书面方式发出通知，据此 通知，会议于 2025 年 4 月 28 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会主席牟乐海先生召集和主持，符合《公司法》和《公司章程》 规定。 证券代码：600587 证券简称：新华医疗 编号：临 2025-012 二、监事会会议审议情况 （一）审议通过《2024 年年度报告全文及摘要》和《2025 年第一季度报告》， 并对公司 2024 年年度报告和 2025 年第一季度报告发表审核意见 公司监事会根据《证券法》、《公开发行证券的公司信息披露内容与格式准 则第 2 号——年度报告的内容与格式（2021 年修订）》及最新修订征求意见稿、 《公开发行证券的公司信息披露编报规则第 15 号——财务报告的一般规定 （2023 年修订）》 ...

第十一届董事会第十八次会议决议公告 证券代码：600587 证券简称：新华医疗 编号：临 2025-011 山东新华医疗器械股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第十八次会议于 2025 年 4 月 18 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 4 月 28 日在公司三楼会议室召开。会议以现场与通讯 相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 （一）审议通过《2024 年年度报告全文及摘要》 董事会审计委员会审议通过了《2024 年年度报告全文及摘要》。 本议案尚需提交股东大会审议。 详见公司于 2025 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披 露的《新华医疗 2024 年年度报告全文及摘要》。 表决结果：同意 11 ...

证券代码：600587 证券简称：新华医疗 编号：临 2025-011 山东新华医疗器械股份有限公司 关于 2024 年度利润分配预案和提请股东大会授权董事会制 定 2025 年中期分红方案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中 的任何虚假记载、误导性陈述或者重大遗漏承担连带责任。 重要内容提示： 每股分配比例：山东新华医疗器械股份有限公司（以下简称"公司"或 "新华医疗"）拟向全体股东每 10 股派发现金红利 2.50 元（含税）。不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持现金派发每股分配比例不变，相应调整现金派发总金额， 并将在相关公告中披露。 公司不会触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以 下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 一、基本情况 （一）公司 2024 年度利润分配预案 经天职国际会计师事务所（特殊普通合伙）审计，新华医疗 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,307,531,823.28, a decrease of 8.74% compared to ¥2,528,538,840.43 in the same period last year[4]. - Net profit attributable to shareholders was ¥160,455,800.07, down 23.97% from ¥211,036,820.12 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥157,702,901.57, reflecting a decline of 24.53% compared to ¥208,965,933.49 in the previous year[4]. - The basic and diluted earnings per share were both ¥0.27, a decrease of 22.86% from ¥0.35 in the same period last year[4]. - The weighted average return on equity decreased to 2.09%, down 0.78 percentage points from 2.87% year-on-year[4]. - Total operating revenue for Q1 2025 was CNY 2,307,531,823.28, a decrease of 8.7% from CNY 2,528,538,840.43 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 161,227,589.00, a decline of 25.1% compared to CNY 215,024,150.02 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, down from CNY 0.35 in Q1 2024[20]. - The company reported a total comprehensive income of CNY 161,227,589.00 for Q1 2025, compared to CNY 215,024,150.02 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,324,351,008.59, a decrease of 1.30% from ¥15,526,375,082.77 at the end of the previous year[5]. - The company's current assets totaled CNY 9,059,086,874.27, down from CNY 9,366,020,874.15, indicating a decrease of about 3.3%[14]. - The total liabilities decreased to CNY 6,848,384,341.13 from CNY 7,237,038,074.90, reflecting a reduction of approximately 5.4%[15]. - Total liabilities amounted to CNY 7,155,288,798.36, a decrease from CNY 7,543,748,934.23 in the previous period[16]. - The company's long-term equity investments increased to CNY 1,518,261,716.52 from CNY 1,506,671,275.58, reflecting a growth of about 0.8%[15]. - The total current liabilities amounted to CNY 6,848,384,341.13, which is a significant portion of the total liabilities[15]. Cash Flow - The net cash flow from operating activities was -¥163,624,921.28, an improvement from -¥213,902,750.72 in the same period last year[4]. - Cash received from sales of goods and services in Q1 2025 was CNY 2,039,406,999.49, a slight decrease from CNY 2,070,468,159.18 in Q1 2024[22]. - The net cash flow from operating activities was -$163.62 million, compared to -$213.90 million in the previous period, indicating an improvement of approximately 23.5%[23]. - Total cash inflow from operating activities was $2.11 billion, while cash outflow was $2.28 billion, resulting in a net cash flow of -$163.62 million[23]. - Cash inflow from investment activities was $1.45 million, while cash outflow was $187.67 million, leading to a net cash flow of -$186.21 million[23]. - Cash inflow from financing activities was $455.10 million, with cash outflow totaling $432.62 million, resulting in a net cash flow of $22.48 million[24]. - The total cash and cash equivalents at the end of the period was $2.44 billion, down from $2.65 billion in the previous period[24]. - Payments to employees amounted to $514.46 million, reflecting a decrease from $537.90 million in the previous period[23]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.50% to ¥7,786,792,401.82 from ¥7,597,127,229.99 at the end of the previous year[5]. - Total equity attributable to shareholders increased to CNY 7,786,792,401.82 from CNY 7,597,127,229.99[16]. Operational Insights - The decline in revenue was primarily due to decreased sales in the medical trading segment[8]. - The company reported non-recurring gains of ¥2,752,898.50, after accounting for tax and minority interests[8]. - Research and development expenses increased to CNY 93,857,263.18 in Q1 2025, up from CNY 83,305,119.71 in Q1 2024, reflecting a focus on innovation[19]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[12]. Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25].

Financial Performance - The company's operating revenue for 2024 reached RMB 10,020,618,625.09, a slight increase of 0.09% compared to RMB 10,011,868,423.40 in 2023[23] - Net profit attributable to shareholders for 2024 was RMB 691,609,558.03, representing a growth of 5.75% from RMB 653,997,275.95 in 2023[23] - The net profit after deducting non-recurring gains and losses was RMB 623,195,651.23, showing a marginal increase of 0.60% compared to RMB 619,448,862.20 in 2023[23] - Cash flow from operating activities decreased significantly by 56.24% to RMB 450,733,485.54 from RMB 1,030,114,479.17 in 2023[23] - The company's total assets at the end of 2024 were RMB 15,526,375,082.77, a decrease of 0.41% from RMB 15,590,329,775.23 in 2023[23] - The net assets attributable to shareholders increased by 3.81% to RMB 7,597,127,229.99 from RMB 7,318,625,200.44 in 2023[23] - Basic earnings per share for 2024 were RMB 1.14, up 3.64% from RMB 1.10 in 2023[25] - The weighted average return on net assets for 2024 was 9.29%, a decrease of 0.18 percentage points from 9.47% in 2023[25] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 151,669,479.75[8] - The cash dividend amount for the year is CNY 151,669,479.75, representing 21.93% of the net profit attributable to ordinary shareholders[155] - The cumulative cash dividend over the last three accounting years is CNY 455,041,722.60, with an average cash dividend ratio of 73.96%[157] Research and Development - The company launched over 100 new products, including key innovations in high-temperature sterilization and 3D imaging technologies[35] - The company has signed 60% more external technology cooperation projects compared to the previous year, enhancing innovation capabilities[36] - The company is recognized as a national key high-tech enterprise and has established multiple provincial-level R&D platforms, contributing to over 100 new key technology innovation projects annually[43] - The company is focusing on upgrading existing products and developing new automated devices, with a registration certificate for fully automated glycosylated hemoglobin equipment obtained in August 2024[47] - The company is committed to technology innovation as a primary driver for growth, emphasizing the importance of talent and innovation in its strategic development[53] Market Expansion and Strategy - The company is expanding its overseas market presence, with successful operations in Indonesia and Saudi Arabia[36] - The company has successfully entered high-end markets such as the EU, achieving its first export sales of multiple products, significantly enhancing its overseas market visibility and share[37] - The company is actively pursuing international market expansion and product certification to enhance its competitive position globally[113] - The company is focusing on market segmentation and precision marketing by conducting in-depth market research and data analysis to tailor marketing strategies based on customer types and consumption habits[112] Operational Efficiency and Cost Management - The company has implemented a VMI inventory management model with core suppliers, effectively reducing internal inventory levels and mitigating supply chain fluctuations[53] - The company has implemented comprehensive cost control measures and optimizing resource allocation to enhance operational efficiency[115] - The company has established partnerships with key industry players to enhance distribution channels and improve market reach[131] Environmental Responsibility - The company invested 1,494,700 CNY in environmental protection during the reporting period[170] - The company has established an environmental management system compliant with GB/T24001-2016 standards to ensure legal and compliant environmental management activities[183] - The company has implemented a clean production approach in its park to promote energy conservation and emission reduction[183] - The company achieved a reduction of 4,776.26 tons in carbon dioxide equivalent emissions through various carbon reduction measures, including a 8.2MW photovoltaic power generation system[184] Corporate Governance - The company ensures compliance with shareholder meeting procedures, safeguarding shareholders' rights and maintaining equal status among all shareholders[122] - The board of directors consists of four independent directors, representing one-third of the board, ensuring the protection of minority shareholders' interests[122] - The company has established various committees, including an audit committee and a remuneration committee, to enhance decision-making processes and reduce risks[122] Legal and Compliance - The company has ongoing litigation with 3M Innovation Co., Ltd. regarding patent infringement, with a settlement amount of RMB 20 million[196] - The company has committed to transparency in its financial disclosures and compliance with relevant regulations[190] - The company has not reported any significant lawsuits or arbitration matters that could materially affect its financial position, aside from the ongoing patent case[195] Employee and Management - The company has a total of 8,135 employees, with 4,132 in the parent company and 4,003 in major subsidiaries[147] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 11.33 million yuan[135] - The management team has a strong background in the medical and financial sectors, enhancing the company's strategic direction[129]